| Side Effects of Procrit: Rapid Growth of some head and neck tumors Rapid growth of metastatic breast cancer Adverse cardiovascular events, including heart attack Formation of blood clots, particularly in patients with kidney failure and patients undergoing orthopedic surgery Increased risk of stroke |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| Call for a FREE case evaluation: (713) 255-2055 |
| companies place profits over the we, as lawyers, should feel a special need to hold them accountable. Without accountability, there can be no positive change." Todd Kelly |
| Procrit Litigation |
All ESAs Work the Same Way
Erythropoiesis stimulating agents (ESAs) such as Procrit, Aranesp, and Epogen are
prescribed to nearly one million patients in the United States each year. A number
of recent studies have found that ESA treatment is associated with potentially fatal
side effects for patients with:
· Anemia caused by cancer rather than by chemotherapy
· Head and neck cancer
· Lung cancer
· Blood transfusions given prior to major surgery
If you have been treated with an ESA such as Procrit and suffered a severe Procrit
side effect, you may be entitled to compensation for your losses. Contact us to
arrange a FREE consultation with an experienced attorney near you.
Procrit Side Effects and Dialysis Risks
In late 2006, The New England Journal of Medicine reported the results of a large
clinical study evaluating Procrit’s benefits and risks in patients with chronic kidney
disease who were not on dialysis. At the time, the product labeling for Procrit
recommended raising a patient’s blood hemoglobin level to no higher than 12 g/dL
with Procrit treatment. The study subjects who were treated with Procrit to raise
their blood hemoglobin level to 13.5 g/dL experienced greater rates of death and
life-threatening Procrit side effects compared to those who were treated to raise
their blood hemoglobin level to 11.3 g/dL.
In practice, almost all kidney dialysis patients in the U.S. are treated with an ESA
such as Procrit, and almost none of them have hemoglobin levels below 11 g/dL
after treatment. In fact, the U.S. Renal Data System reported that about 50% of
dialysis patients have levels of more than 12 g/dL and close to 20% have levels
above 13 g/dL after ESA treatment.
According to a New York Times investigative report, some scientists believe that
kidney dialysis patients, most of whom are on Medicare, are being over-medicated
with ESAs because dialysis clinics reap larger profits for providing higher doses of
ESAs.
Have You Suffered a Procrit Side Effect?
If you have suffered a serious Procrit side effect, you need to ensure your rights are
protected. You may be eligible to recover damages including medical bills, pain and
suffering, loss of enjoyment of life, and more. Contact us today to discuss your
legal options.
